SVT-40776 in Patients Suffering From Overactive Bladder Syndrome

This study has been completed.
Sponsor:
Information provided by:
Salvat
ClinicalTrials.gov Identifier:
NCT00507169
First received: July 25, 2007
Last updated: June 7, 2011
Last verified: June 2011
  Purpose

The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine


Condition Intervention Phase
Overactive Bladder (OAB)
Drug: SVT-40776
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Salvat:

Study Start Date: September 2006
Study Completion Date: September 2007
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients suffering from OAB for at least 6 months prior to inclusion

Exclusion Criteria:

  • Pregnant and breastfeeding women
  • Any medical condition or need for co-medication which interferes with the drug under investigation (SVT-40776) or the comparator (tolterodine)
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Medical Director, Laboratorios SALVAT
ClinicalTrials.gov Identifier: NCT00507169     History of Changes
Other Study ID Numbers: 40776ORII/05IA01
Study First Received: July 25, 2007
Last Updated: June 7, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Urinary Bladder, Overactive
Urinary Bladder Diseases
Urologic Diseases
Urological Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on April 15, 2014